New PET tracer could reveal hidden immune activity in tumors
NCT ID NCT05259709
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 36 times
Summary
This early-phase study tests a new imaging drug (89Zr-DFO-REGN5054) that may help doctors see immune cells inside tumors using PET scans. About 50 adults with advanced solid cancers who are also receiving the immunotherapy cemiplimab will take part. The main goal is to check safety and how the body handles the imaging agent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UMC Groningen
RECRUITINGGroningen, 9700 RB, Netherlands
Conditions
Explore the condition pages connected to this study.